HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study
- Conditions
- Relapsed or Refractory Lymphoma
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 28
- Registration Number
- NCT05720767
- Locations
- 🇺🇸
PPD Austin, Austin, Texas, United States
A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 61
- Registration Number
- NCT05713110
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
- Conditions
- Relapsed or Refractory Lymphoma
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 59
- Registration Number
- NCT05602597
- Locations
- 🇺🇸
QPS- Miami, Miami, Florida, United States
HMPL-523 Food Effect and Proton Pump Inhibitor Study
- Conditions
- Relapsed or Refractory Lymphoma
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 26
- Registration Number
- NCT05571787
- Locations
- 🇺🇸
PPD Austin, Austin, Texas, United States
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
- Conditions
- Advanced Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 265
- Registration Number
- NCT05522231
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
🇨🇳Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma
- Conditions
- Relapsed/Refractory Follicular Lymphoma With EZH2
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 42
- Registration Number
- NCT05467943
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China
A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm
- Conditions
- Advanced Tumors
- Interventions
- Drug: HMPL-A83 injection
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 99
- Registration Number
- NCT05429008
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳Shandong Cancer Hospital, Shandong, Jinan, China
🇨🇳Shanghai Orient Hospital, Shanghai, Shanghai, China
Fruquintinib DDI Study With P-gp and BCRP Substrates
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 32
- Registration Number
- NCT05368805
- Locations
- 🇺🇸
PPD Development, Austin, Texas, United States
Fruquintinib Hepatic Impairment Study
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 16
- Registration Number
- NCT05216367
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Fruquintinib Renal Impairment Study
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 24
- Registration Number
- NCT05216354
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States